All In MedTech

FDA Clearance Tracker · P110033-S090

Juvederm Voluma XC

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jan 17, 2025 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Jan 17, 2025

Approved

Time to decision

86 days

Received Oct 23, 2024. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P110033-S090
Device name
Juvederm Voluma XC
Applicant
Allergan
Applicant location
Irvine, CA
Received
Oct 23, 2024
Decided
Jan 17, 2025
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P110033

Device type

Device class
Class III

Every decision under product code LMH

FDA's approval statement

As written in FDA's record.

Approval for removing the lower limit of the free HA specification for the manufacture of Juvederm Voluma XC.

Source documents

Other decisions for Allergan

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.